Chengdu Olymvax Biopharmaceuticals Inc.SSE: 688319

(688319)"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Voluntary Disclosure of Receipt of the Phase III Clinical Study Summary Report for the Recombinant Staphylococcus aureus Vaccine (E. coli)

· Issued by Chengdu Olymvax Biopharmaceuticals Inc. via Shanghai Stock Exchange

Filed with SSE · Stock code 688319 ·

On 6ix: 6ix.com/news/688319chengdu-olymvax-biopharmaceuticals-incannouncement-on-voluntary-disclosure-of-receipt-of-the-phase-iii-clinical-study-summary-report-for-the-recombinant-staphylococcus-aureus-vaccine-e-coli

Announcement on Voluntary Disclosure of Receipt of the Phase III Clinical Study Summary Report for the Recombinant Staphylococcus aureus Vaccine (E. coli)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

6ix is reading this filing.

View original source (Shanghai Stock Exchange)Chengdu Olymvax Biopharmaceuticals Inc. on 6ix

Story so far

Earlier from Chengdu Olymvax Biopharmaceuticals

All Chengdu Olymvax Biopharmaceuticals news releases